Stroke is one of the leading causes of death and disability worldwide, making early and accurate diagnosis critical to improving patient outcomes. While imaging techniques like CT scans and MRIs are widely used, they have limitations in detecting stroke at its earliest stages and may not always be accessible.
Recent research highlights the potential of blood-based biomarkers to provide valuable insights into stroke occurrence, severity, and prognosis. Biomarkers such as brain-derived tau (BD-tau), neurofilament light (NfL), glial fibrillary acidic protein (GFAP), tau, and inflammatory cytokines offer a window into neuronal injury and neuroinflammation, helping researchers and clinicians better understand stroke pathology.
This publication brief explores:
- The role of BD-tau in assessing stroke severity and predicting recovery.
- How NfL and GFAP work alongside BD-tau to improve stroke prognosis.
- The importance of ultra-sensitive biomarker detection in stroke research.
- How Simoa® technology enables precise, high-sensitivity measurement of key biomarkers.
Download the publication brief to learn more about the latest advances in blood-based biomarkers for stroke research.
Related Posts
Mapping the Tau Cascade: New Insights from p-Tau 205 and p-Tau 212 for Disease Staging and Monitoring
NPTX2: A Synaptic Biomarker of Circuit Integrity, Cognitive Resilience, and Neurodegeneration
Neurology
Advancing Translational Neuroscience with the Simoa Mammalian GFAP Assay
Publication Brief Understanding astrocyte biology is essential for advancing translational neuroscience. GFAP has emerged as a leading biomarker of CNS injury, and Simoa® technology now enables its ultra-sensitive detection directly…
Proteomics in Transition: From Discovery to Diagnostic Relevance
Proteomics is moving beyond broad discovery to deliver real-time, clinically meaningful insights. At the forefront is Quanterix’s Simoa® digital immunoassay technology, enabling ultra-sensitive, reproducible detection of low-abundance biomarkers in areas…
Neurology
Beyond Blood: Expanding Simoa Applications in Urine, Saliva, Sweat, and Tears
Publication Brief The Quanterix Simoa® platform, known for ultrasensitive detection in plasma, serum, and CSF, now delivers the same performance in alternative matrices—urine, saliva, sweat, and tears. This publication brief…
Immunology
Simoa® IL-17A Advantage PLUS: Potential Biomarker Applications in Health and Disease
App Note IL-17A is a potent pro-inflammatory cytokine that plays critical roles in inflammatory responses, host defense against infections, and tissue regeneration. This application note delves into the physiological and…
Neurology
Beyond Blood: Tear Fluid as a Window into Biomarker Discovery
While blood and CSF have long dominated biomarker research, tear fluid is emerging as a scientifically relevant, non-invasive matrix for detecting systemic and neurological biomarkers. Produced by lacrimal glands and…
Neurology
Sweat As A Non-Invasive Matrix for Cytokine Detection Using Simoa®
Inflammatory cytokines like IL-6, IL-10, and TNF-α are central to understanding aging, immune dysregulation, and chronic disease. With eccrine glands distributed across the body, sweat offers a non-invasive, physiologically relevant…